CDXC Quote, Financials, Valuation and Earnings

Better Choice has a net margin of 24.65% compared to ChromaDex's net margin of 13.42%. ChromaDex's return on equity of 25.36% beat Better Choice's return on equity of -199.75%.

ChromaDex has a consensus price target of $8.82, signalling upside risk potential of 12.5%. On the other hand Better Choice has an analysts' consensus of -- which suggests that it could grow by 549.35%. Given that Better Choice has higher upside potential than ChromaDex, analysts believe Better Choice is more attractive than ChromaDex.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.863% more volatile than S&P 500. In comparison Better Choice has a beta of 0.543, suggesting its less volatile than the S&P 500 by 45.729%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Better Choice offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ChromaDex pays -- of its earnings as a dividend. Better Choice pays out -- of its earnings as a dividend.

ChromaDex quarterly revenues are $29.1M, which are larger than Better Choice quarterly revenues of $11.4M. ChromaDex's net income of $7.2M is higher than Better Choice's net income of $1.5M. Notably, ChromaDex's price-to-earnings ratio is 78.56x while Better Choice's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 6.11x versus 0.05x for Better Choice. Usually stocks with elevated PS ratios are considered overvalued.

The Kraft Heinz has a net margin of 24.65% compared to ChromaDex's net margin of 32.41%. ChromaDex's return on equity of 25.36% beat The Kraft Heinz's return on equity of 5.57%.

ChromaDex has a consensus price target of $8.82, signalling upside risk potential of 12.5%. On the other hand The Kraft Heinz has an analysts' consensus of $33.04 which suggests that it could grow by 9.31%. Given that ChromaDex has higher upside potential than The Kraft Heinz, analysts believe ChromaDex is more attractive than The Kraft Heinz.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.863% more volatile than S&P 500. In comparison The Kraft Heinz has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.734%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Kraft Heinz offers a yield of 5.29% to investors and pays a quarterly dividend of $0.40 per share. ChromaDex pays -- of its earnings as a dividend. The Kraft Heinz pays out 70.37% of its earnings as a dividend. The Kraft Heinz's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ChromaDex quarterly revenues are $29.1M, which are smaller than The Kraft Heinz quarterly revenues of $6.6B. ChromaDex's net income of $7.2M is lower than The Kraft Heinz's net income of $2.1B. Notably, ChromaDex's price-to-earnings ratio is 78.56x while The Kraft Heinz's PE ratio is 13.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 6.11x versus 1.42x for The Kraft Heinz. Usually stocks with elevated PS ratios are considered overvalued.

Lifevantage has a net margin of 24.65% compared to ChromaDex's net margin of 3.76%. ChromaDex's return on equity of 25.36% beat Lifevantage's return on equity of 26.66%.

ChromaDex has a consensus price target of $8.82, signalling upside risk potential of 12.5%. On the other hand Lifevantage has an analysts' consensus of $32.50 which suggests that it could grow by 90.39%. Given that Lifevantage has higher upside potential than ChromaDex, analysts believe Lifevantage is more attractive than ChromaDex.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.863% more volatile than S&P 500. In comparison Lifevantage has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.934%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifevantage offers a yield of 0.94% to investors and pays a quarterly dividend of $0.04 per share. ChromaDex pays -- of its earnings as a dividend. Lifevantage pays out 236.3% of its earnings as a dividend.

ChromaDex quarterly revenues are $29.1M, which are smaller than Lifevantage quarterly revenues of $67.8M. ChromaDex's net income of $7.2M is higher than Lifevantage's net income of $2.6M. Notably, ChromaDex's price-to-earnings ratio is 78.56x while Lifevantage's PE ratio is 30.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 6.11x versus 1.04x for Lifevantage. Usually stocks with elevated PS ratios are considered overvalued.

Laird Superfood has a net margin of 24.65% compared to ChromaDex's net margin of -3.43%. ChromaDex's return on equity of 25.36% beat Laird Superfood's return on equity of -14.01%.

ChromaDex has a consensus price target of $8.82, signalling upside risk potential of 12.5%. On the other hand Laird Superfood has an analysts' consensus of $13.00 which suggests that it could grow by 143.45%. Given that Laird Superfood has higher upside potential than ChromaDex, analysts believe Laird Superfood is more attractive than ChromaDex.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.863% more volatile than S&P 500. In comparison Laird Superfood has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Laird Superfood offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ChromaDex pays -- of its earnings as a dividend. Laird Superfood pays out -- of its earnings as a dividend.

ChromaDex quarterly revenues are $29.1M, which are larger than Laird Superfood quarterly revenues of $11.6M. ChromaDex's net income of $7.2M is higher than Laird Superfood's net income of -$398.4K. Notably, ChromaDex's price-to-earnings ratio is 78.56x while Laird Superfood's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 6.11x versus 1.23x for Laird Superfood. Usually stocks with elevated PS ratios are considered overvalued.